💊Pharmaconomics
FDA catalyst calendar

Every biotech FDA catalyst — with the receipt to prove it.

The free FDA-catalyst calendar for biotech traders. PDUFA dates, advisory committees and trial readouts, each carrying its primary source and a live "verified" stamp.

88.5 d
Median detection latency
from source publish → our catalog · goal < 24h
100%
Upcoming with a receipt
779 of 779 carry a primary source
779
Upcoming catalysts
2673 sources · 1495 logged changes
Baseline building
Zero-missed streak
starts once tracked catalysts resolve
All PDUFA AdCom Phase 3 Phase 2 Phase 1 Approval

88 catalysts · filtered

NBP
NovaBridge Biosciences
Approval AI-extracted
Giva
first-line treatment of gastric cancer
T-minus 132 days ~ Dec 31, 2026
SEC 6-K verified 2mo ago
Countdown card →
GOSS
Gossamer Bio, Inc.
Approval AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
T-minus 192 days Mar 1, 2027
SEC 8-K verified 2mo ago
Countdown card →

Recently caught

Field changes we detected and logged — the audit trail behind every receipt.

Phase 2 LGVN status upcoming → unknown (garbage-cluster: 5 tickers share 2026-08-31) 2mo ago
Phase 2 ACAD status upcoming → unknown (garbage-cluster: 5 tickers share 2026-08-31) 2mo ago
Catalyst AVIR status upcoming → unknown (garbage-cluster: 5 tickers share 2026-08-31) 2mo ago
PDUFA PTGX status upcoming → unknown (garbage-cluster: 5 tickers share 2026-08-31) 2mo ago
Phase 3 RHHBY status upcoming → unknown (garbage-cluster: 5 tickers share 2026-08-31) 2mo ago
AdCom IFRX status upcoming → unknown 2mo ago

How it works

We watch the primary sources

FDA press & AdComm calendars, SEC 8-K/6-K filings, company PRs and ClinicalTrials.gov — automatically, around the clock.

Every catalyst gets a receipt

Each date links to the exact document it came from and shows when we last re-verified it. No unsourced claims.

Free, no login

The whole calendar is open. Our edge is being faster and more honest than the paywalled incumbents.